What RefinedScience does

RefinedScience is a precision oncology company that operates a single-cell multi-omics platform combining longitudinal clinical data, biobank samples, and EHR records with AI-powered analysis tools to support pharmaceutical drug development. The company is structured as a joint venture between the University of Colorado Anschutz Medical Campus and UCHealth, headquartered in Aurora, Colorado, and was formally established in 2024. Its proprietary technology stack centers on a 41TB single-cell database covering 300+ AML patients with CITE-seq surface protein mapping and single-cell transcriptomics, alongside four named AI tools (scExploreR, Marksman, Scout, PULSE), 700+ functional assays, and 12 standardized protocols. RefinedScience positions itself as a biology-first partner to pharma rather than a pure software vendor, emphasizing that single-cell resolution of clinically annotated human tissue addresses the 25% Phase II success rate problem in oncology.

RefinedScience generates revenue primarily through professional services engagements with pharmaceutical and biotechnology partners, plus co-development/licensing partnerships in ADC discovery. Its service offering is segmented across Discovery (target identification, validation, patient stratification), Translational Validation (resistance profiling, rational combinations, preclinical development), and Clinical Development (patient stratification, biomarker analysis, external dataset comparison, synthetic trial simulation, CDx discovery). The ADC Discovery Program in AML is a distinct offering that uses the platform to identify and validate novel ADC targets for co-development with partners. Pricing is custom and not publicly disclosed, and all engagements are shaped around specific biology problems rather than a fixed service catalog. Named customers and partners include OncoVerity (Phase II cusatuzumab AML support), an unnamed Global Pharmaceutical Company and Large Pharma for AML profiling and biomarker work, and ImCheck Therapeutics (work supporting FDA Breakthrough Therapy Designation and contributing to Ipsen's €1B acquisition of ImCheck, with a follow-on engagement with Ipsen).

Go-to-market is exclusively direct enterprise B2B: no self-serve, marketplace, or e-commerce channels. The company engages prospects through industry conferences (AACR), LinkedIn, website content, and direct outreach via [email protected]. Distribution was extended in October 2025 through a multi-year strategic collaboration with Verily (Alphabet), UCHealth, and CU Anschutz, which placed RefinedScience's longitudinal AML dataset on the Verily Exchange and validated 95%+ accuracy and 30x faster data extraction benchmarks using Verily Refinery. The company also spun out OncoVerity as a clinical-stage vehicle to advance the cusatuzumab Phase II program, with RefinedScience providing translational and clinical operations support.

Name

RefinedScience

Legal name

RefinedScience

Website

https://refinedscience.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

RefinedScience is a precision oncology joint venture between CU Anschutz and UCHealth that combines a 41TB single-cell database with proprietary AI tools to provide biology-first drug development services to pharmaceutical partners across target validation, translational research, and clinical execution.

Ownership category

akta.pro rank

Product category

Precision Oncology Drug Development Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Decision Support & Workflow Integration (EHR/oncology systems) (HLAAANAE)

akta.pro secondary industries

Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Translational Medicine & Biomarkers (HLAIALAF), Clinical Trial Site Operations & Study Coordination (HLAGACAE)

Keywords

• Precision oncology services
• Single-cell multi-omics
• Pharma R&D services
• ADC discovery
• Clinical data analytics

Headquarters

HQ city

Aurora

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Pharma R&D Services: Biology-first drug development support services provided to pharmaceutical partners across discovery, translational validation, and clinical development stages. Engagements are shaped around specific biology problems and include target validation, patient stratification, and clinical trial design support.
2. ADC Discovery Partnerships: Co-development partnerships for ADC (antibody-drug conjugate) target discovery in AML. Seeking partners with ADC platforms, antibody engineering, or clinical infrastructure to co-develop programs toward lead candidates.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

RefinedScience provides biology-first precision oncology drug development services to pharmaceutical partners, combining a 41TB single-cell database (300+ AML patients) with proprietary AI tools (scExploreR, Marksman, Scout, PULSE) and 700+ functional assays. The company engages pharma partners from target identification through clinical execution, offering custom solutions including ADC target discovery in AML, patient stratification, and clinical trial design support across seven oncology indications.

Product overview

RefinedScience is a biology-first precision oncology company offering an integrated platform combining four core capabilities: Deep Clinical & Multimodal Data (unified access to longitudinal patient data, biobank samples, and EHR data across 7 oncology indications), AI-Powered Analysis (proprietary tools including scExploreR, Marksman, Scout, and PULSE supporting 1,000+ AI-generated reports), Biological Validation (700+ functional assays including drug testing on primary patient tissue and patient-derived organoids), and Expert Multidisciplinary Team expertise. The platform supports pharma partners through Pharma R&D Services spanning Discovery, Translational Validation, and Clinical Development phases, as well as a dedicated ADC Discovery Program for AML. A longitudinal AML dataset with 300+ patients is available via the Verily Exchange partnership. The company operates as a joint venture between CU Anschutz and UCHealth, with a spinout company OncoVerity advancing Phase II clinical programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharma R&D Services Integrated drug development support services for pharmaceutical partners across the full development lifecycle from target identification through clinical execution. Services include Discovery (target identification, validation, patient stratification), Translational Validation (resistance mechanism profiling, rational combination identification, preclinical development), and Clinical Development (patient stratification, biomarker analysis, external dataset comparison, synthetic trial simulation, CDx discovery).
• ADC Discovery Program A systematic ADC target discovery program for acute myeloid leukemia (AML) utilizing the 41TB single-cell database, tumor-initiating cell models, CITE-seq surface antigen mapping, and functional primary tissue validation to identify and validate novel ADC targets. Offered as co-development partnerships with ADC platform companies, antibody engineering firms, and clinical infrastructure partners.
• RefinedScience Longitudinal AML Dataset A longitudinal Acute Myeloid Leukemia dataset covering 300+ venetoclax and azacitidine-treated patients with clinical and CITE-seq data, made available on the Verily Exchange platform as a specialized research dataset for precision health AI applications.

Quantifiable outcome

• Greater than 95% accuracy on complex variables like karyotype strings and NGS mutations
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Verily (Alphabet)coreStrategic or Co-development Partner · 1 October 2025Multi-year strategic collaboration announced October 2025 between Verily, UCHealth, CU Anschutz, and RefinedScience to create AI-ready biomedical data pipelines and develop novel AI/ML models. Initial collaboration demonstrated 95%+ accuracy and 30x faster data extraction from AML patient records. RefinedScience longitudinal AML dataset (300+ patients) available on Verily Exchange.
• CU Anschutz (University of Colorado Anschutz Medical Campus)coreStrategic or Co-development PartnerJoint venture partner providing institutional access to academic research capabilities, clinical data infrastructure, and world-class AML and ADC advisors. CU Anschutz has committed to multi-year expansion scaling data solutions to population-level datasets across cardiovascular disease, neuroscience, and ophthalmology.
• UCHealthcoreStrategic or Co-development PartnerJoint venture partner providing longitudinal patient data, biobank samples, and EHR data access across 7 oncology indications. Unified access to clinical infrastructure enables patient-linked single-cell datasets that external vendors cannot replicate.
• OncoVeritycoreStrategic or Co-development PartnerSpinout company with RefinedScience providing end-to-end clinical trial support. OncoVerity CEO Max Calao and CMO Mike Boyiadzis lead the Phase II cusatuzumab program supported by RefinedScience's translational and clinical operations capabilities.
• IpsenminorStrategic or Co-development PartnerFollowing Ipsen's €1B acquisition of ImCheck Therapeutics, RefinedScience maintains a follow-on engagement with Ipsen in ADC development. RefinedScience work on ImCheck's Phase I program contributed to FDA Breakthrough Therapy Designation and was included in acquisition rationale.
• ImCheck TherapeuticsminorStrategic or Co-development PartnerSupported ImCheck's Phase I program through real-world external dataset comparison and propensity-matched analysis. Work was included in FDA Breakthrough Therapy Designation application and contributed to biological credibility supporting company's acquisition by Ipsen.

Scale indicators10 records

Recent moves5 records

Expansion highlights2 records

Direct peers

• 10x Genomics: Leading provider of single-cell sequencing and multi-omics technologies (Chromium, Visium, Xenium). Directly comparable to RefinedScience on the single-cell technology foundation underlying the company's CITE-seq and transcriptomics platform.
• Caris Life Sciences: Molecular profiling and AI company integrating multi-omics, AI, and clinical data to support biopharma drug development and patient care in oncology. Closely comparable business model of monetizing proprietary molecular+clinical datasets through pharma services and ADC/biomarker partnerships.
• Personalis: Genomic profiling company with biopharma services business in oncology, including tumor profiling and MRD detection. Comparable in serving pharma partners with molecular data products and analytical services to support clinical development, particularly in oncology.
• Adaptive Biotechnologies: Immune profiling company combining sequencing and AI for drug discovery and clinical development support. Comparable in offering proprietary biological data assets plus pharma R&D services, particularly in immune-mediated and hematologic indications.

Broad incumbents

• Tempus AI: Precision medicine data platform combining clinical data, molecular profiling, and AI to support both patient care and biopharma drug development. Operates at much greater scale than RefinedScience across many indications, with overlapping value proposition of integrating clinical and molecular data for pharma partners.
• Foundation Medicine: Subsidiary of Roche providing comprehensive genomic profiling for oncology patients and biopharma partners. Comparable in delivering molecular profiling plus biopharma services in oncology, though at significantly larger scale and broader indication coverage.

Emerging players

• Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology and machine learning for precision drug development. Comparable in using proprietary data and AI tooling to improve target identification and clinical translation, though focused on building an internal pipeline rather than pharma services.
• Schrödinger: Computational drug discovery platform combining physics-based simulation and AI for pharma R&D. Comparable in the AI-enabled drug development category, though RefinedScience's biology-first approach with patient-linked tissue data is a meaningful differentiation.
• Exscientia: AI-driven precision medicine drug discovery company combining patient data, AI, and automated lab capabilities. Comparable in merging biology data with AI to enable precision drug development, particularly in oncology.

Others

• Verily: Alphabet's precision health technology company and RefinedScience's strategic partner. Operates in adjacent precision health AI space and is also a distribution partner via Verily Exchange, making it both an enabler and a potential competitor in AI-ready biomedical data infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/refinedscience

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RefinedScience